MedTrace Logo

Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients

NCT01876186 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2015-07-07

No results posted yet for this study

Summary

To investigate whether prolonged period of treatment (6 months) can have a better therapeutic outcome than conventional period (3 months) of antimuscarinics.

Conditions

  • Overactive Bladder Syndrome

Interventions

DRUG

Solifenacin for 12 weeks

Solifenacin 5 mg one a day for 12 weeks

DRUG

Solifenacin for 24 weeks

Solifenacin 5 mg once a day for 24 weeks

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Ho-Hsiung Lin, MD, PhD · National Taiwan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01876186 on ClinicalTrials.gov